Medicamento é “altamente seguro, amplamente disponível e de baixo custo”, garante Pierre Kory
O Senado dos Estados Unidos resolveu debater formas de tratamento contra a covid-19. Nesse sentido, o Comitê de Segurança Interna e Assuntos Governamentais da Casa realizou audiência na última semana para discutir o assunto. Para isso, médicos tiveram direito a darem depoimentos. Um deles foi Pierre Kory, presidente da organização Frontline Covid-19 Critical Care Alliance (FCCCA), que defendeu o uso da ivermectina em ações de combate ao novo coronavírus.
Leia mais: “No Senado dos EUA, médico defende ivermectina contra o novo coronavírus”
Segundo o executivo do FCCCA, o medicamento se mostrou eficaz em quase todas as etapas em relação ao tratamento de pacientes com covid-19. Ele destacou, aliás, que o remédio pode ser usado até como modo de prevenir o contágio. “Estudos estão demonstrando a terapêutica potência e segurança da ivermectina na prevenção da transmissão e progressão da doença em quase todos”, comentou Kory diante dos parlamentares norte-americanos presentes no comitê realizado no último dia 8.
“[É algo] altamente seguro, amplamente disponível e de baixo custo”
O médico ainda chamou a atenção para o fato de a ivermectina não fazer parte de medicamentos considerados de alto custo. “[É algo] altamente seguro, amplamente disponível e de baixo custo”, enfatizou Kory em seu discurso. Nesse sentido, ele pediu para que demais especialistas em saúde e autoridades dos Estados Unidos se unam para definições de protocolos de tratamento contra a covid-19 que façam uso da ivermectina. De acordo com ele, estudos mostram que a substância está ajudando a salvar vidas.
Assista ao vídeo do depoimento de Pierre Kory ao Senado dos Estados Unidos:
https://www.youtube.com/watch?v=Z2fzoF3qB3k
Estamos vivendo um momento sui generis: ouvimos tanta negatividade da midia ( que só ganha audiencia e dinheiro com noticia ruim) que preferimos acreditar exclusivamente nos reporteres e seus entrevistados selecionados, do que ter uma segunda opinião, mesmo que venha de médicos e cientistas altamente qualificados… que pena chegarmos neste ponto!
A propósito, leiam o pre-print do dr Pierre Kory : http://www.flccc.net
NÃO EXISTE NEM UM ESTUDO QUE COMPORVA QUALQUER TIPO DE PREVENÇÃO OU COMBATE AO COVID 19… ISTO É FAKE NEWS.
Voce ja pesquisou? Aqui tem 40 estudos que todos comprova:
1.Afsar et al., SSRN., Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting, https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3734478.
2.Ahmed et al., International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.11.191, A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, https://www.sciencedirect.com/science/article/pii/S1201971220325066.
3.Alam et al., European Journal ofMedical and Health Sciences, doi:10.24018/ejmed.2020.2.6.599, Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study, https://ejmed.org/index.php/ejmed/article/view/599.
4.Altman, D., BMJ, doi:10.1136/bmj.d2304, How to obtain the P value from a confidence interval, https://www.bmj.com/content/343/bmj.d2304.
5.Altman (B) et al., BMJ, doi:10.1136/bmj.d2090, How to obtain the confidence interval from a P value, https://www.bmj.com/content/343/bmj.d2090.
6.Anglemyer et al., Cochrane Database of Systematic Reviews 2014, Issue 4, doi:10.1002/14651858.MR000034.pub2, Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials, https://www.cochranelibrary.com/cd..0.1002/14651858.MR000034.pub2/full.
7.Behera et al., medRxiv, doi:10.1101/2020.10.29.20222661v1, Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study, https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1.
8.Bernigaud et al., Annals of Dermatology and Venereology, doi:10.1016/j.annder.2020.09.231, Ivermectin benefit: from scabies to COVID-19, an example of serendipity, https://www.sciencedirect.com/science/article/pii/S015196382030627X.
9.Budhiraja et al., medRxiv, doi:10.1101/2020.11.16.20232223, Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience, https://www.medrxiv.org/content/10.1101/2020.11.16.20232223v1.
10.Cadegiani et al., medRxiv, doi:10.1101/2020.10.31.20223883, Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients, https://www.medrxiv.org/content/10.1101/2020.10.31.20223883v1.
11.Camprubí et al., PLoS ONE, 15:11, doi:10.1371/journal.pone.0242184, Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients, https://journals.plos.org/plosone/..le?id=10.1371/journal.pone.0242184.
12.Carvallo et al., medRxiv, doi:10.1101/2020.09.10.20191619, Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19, https://www.medrxiv.org/content/10.1101/2020.09.10.20191619v1.
13.Carvallo (B) et al., Journal of Biomedical Research and Clinical Investigation, doi:10.31546/2633-8653.1007, Study of the Efficacy and Safety of Topical Ivermectin + Iota-Carrageenan in the Prophylaxis against COVID-19 in Health Personnel, https://medicalpressopenaccess.com/upload/1605709669_1007.pdf.
14.Carvallo (C) et al., NCT04425850, Usefulness of Topic Ivermectin and Carrageenan to Prevent Contagion of Covid 19 (IVERCAR), https://clinicaltrials.gov/ct2/show/results/NCT04425850.
15.Chaccour et al., Research Square, doi:10.21203/rs.3.rs-116547/v1, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with mild COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial, https://www.researchsquare.com/article/rs-116547/v1.
16.Chachar et al., International Journal of Sciences, 9:31-35, doi:10.18483/ijSci.2378, Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients, https://www.ijsciences.com/pub/article/2378.
17.Concato et al., NEJM, 342:1887-1892, doi:10.1056/NEJM200006223422507, https://www.nejm.org/doi/full/10.1056/nejm200006223422507.
18.Deaton et al., Social Science & Medicine, 210, doi:10.1016/j.socscimed.2017.12.005, Understanding and misunderstanding randomized controlled trials, https://www.sciencedirect.com/science/article/pii/S0277953617307359.
19.Deng, H., PyMeta, Python module for meta-analysis, http://www.pymeta.com/.
20.Elgazzar et al., Research Square, doi:10.21203/rs.3.rs-100956/v2, Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic, https://www.researchsquare.com/article/rs-100956/v3.
21.Elgazzar (B) et al., Research Square, doi:10.21203/rs.3.rs-100956/v2, Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic, https://www.researchsquare.com/article/rs-100956/v3.
22.Espitia-Hernandez et al., Biomedical Research, 31:5, Effects of Ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study, https://www.biomedres.info/biomedi..-proof-of-concept-study-14435.html.
23.Gorial et al., medRxiv, doi:10.1101/2020.07.07.20145979, Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial), https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1.
24.Hashim et al., medRxiv, doi:10.1101/2020.10.26.20219345, Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq, https://www.medrxiv.org/content/10.1101/2020.10.26.20219345v1.
25.Hellwig et al., International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106248, A COVID-19 Prophylaxis? Lower incidence associated with prophylactic administration of Ivermectin, https://www.sciencedirect.com/science/article/pii/S0924857920304684.
26.Khan et al., Archivos de Bronconeumología, doi:10.1016/j.arbres.2020.08.007, Ivermectin treatment may improve the prognosis of patients with COVID-19, https://www.sciencedirect.com/science/article/pii/S030028962030288X.
27.Lee et al., Arch Intern Med., 2011, 171:1, 18-22, doi:10.1001/archinternmed.2010.482, Analysis of Overall Level of Evidence Behind Infectious Diseases Society of America Practice Guidelines, https://jamanetwork.com/journals/j..nternalmedicine/fullarticle/226373.
28.Mahmud et al., Clinical Trial Results, NCT04523831, Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection, https://clinicaltrials.gov/ct2/show/results/NCT04523831?view=results.
29.McLean et al., Open Forum Infect. Dis. September 2015, 2:3, doi:10.1093/ofid/ofv100, Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525010/.
30.Niaee et al., Research Square, doi:10.21203/rs.3.rs-109670/v1, Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial, https://www.researchsquare.com/article/rs-109670/v1.
31.Nichol et al., Injury, 2010, doi: 10.1016/j.injury.2010.03.033, Challenging issues in randomised controlled trials, https://www.injuryjournal.com/article/S0020-1383(10)00233-0/fulltext.
32.Podder et al., IMC J. Med. Science, 14:2, July 2020, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomised controlled study, http://imcjms.com/registration/journal_abstract/353.
33.Rajter et al., Chest, doi:10.1016/j.chest.2020.10.009, Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study), https://www.sciencedirect.com/science/article/pii/S0012369220348984.
34.Shouman et al., NCT04422561, Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contacts with Patients of COVID-19, https://clinicaltrials.gov/Provide..cs/61/NCT04422561/Prot_SAP_000.pdf.
35.Soto-Becerra et al., medRxiv, doi:10.1101/2020.10.06.20208066, Real-World Effectiveness of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: Results of a target trial emulation using observational data from a nationwide Healthcare System in Peru, https://www.medrxiv.org/content/10.1101/2020.10.06.20208066v1.
36.Spoorthi et al., IAIM, 2020, 7:10, 177-182, Utility of Ivermectin and Doxycycline combination for the treatment of SARSCoV-2, http://iaimjournal.com/wp-content/..oads/2020/10/iaim_2020_0710_23.pdf.
37.Sweeting et al., Statistics in Medicine, doi:10.1002/sim.1761, What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data, https://onlinelibrary.wiley.com/doi/10.1002/sim.1761.
38.Treanor et al., JAMA, 2000, 283:8, 1016-1024, doi:10.1001/jama.283.8.1016, Efficacy and Safety of the Oral Neuraminidase Inhibitor Oseltamivir in Treating Acute Influenza: A Randomized Controlled Trial, https://jamanetwork.com/journals/jama/fullarticle/192425.
39.Vallejos et al., Coronavirus in Argentina: Warnings and evidence on the consumption of ivermectin against Covid-19, https://totalnewsagency.com/2020/1..de-ivermectina-contra-el-covid-19/.
40.Zhang et al., JAMA, 80:19, 1690, doi:10.1001/jama.280.19.1690, What’s the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes, https://jamanetwork.com/journals/jama/fullarticle/188182.
Aprenda a escrever
Muito comunista no Brasil.